Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2005

View Archived Issues

Novel IKK-2 inhibitor shows promise for the treatment of rheumatoid arthritis

Phase I for Vernalis/Serono collaborative compound

Pfizer to acquire Angiosyn

MedImmune files IND for phase I study of RSV/PIV-3 candidate vaccine

Compound from Merck & Co./Karo Bio collaboration enters clinic

BCX-2798 prevents lethal synergism between paramyxovirus and S. pneumoniae in mice

Preclinical data indicate efficacy of the VEGF pathway-targeted siRNA, ICS-283

New phase III and II data for SPP-100 for hypertension

Macugen now available

Bolder BioTechnology awarded SBIR grant to develop arthritis treatment

European CHMP reviews COX-2 inhibitors

Zalypsis enters phase I

Schering-Plough to acquire NeoGenesis

Aclasta recommended for approval for Paget's disease in Europe

Cotara enters new glioblastoma multiforme study

IND acceptance allows initiation of phase I trials of oleoyl estrone

Thalidomide receives orphan drug status in Japan

Solvay completes acquisition of Neopharma

Phase III data on the safety and analgesic efficacy of M6G in postoperative pain

Good safety profile reported for CEA-TRICOM vaccines in advanced cancer patients

In vitro evidence for the antitumor effects of oleic acid in breast cancer

Update on the pharmacological effects and safety profile of GHRP-2

Agents for the treatment of Alzheimer's disease reported by Merck

Scientists at GlaxoSmithKline describe histamine H3 receptor antagonists

Bayer presents DGAT-1 inhibitors for obesity and related disorders

New agents for type 2 diabetes mellitus covered by Merck patent

Agents for HIV infection disclosed in a patent

New 5-HT2A receptor antagonists for CNS disorders designed at Merck

New compounds for treatment of obesity identified by Novo Nordisk team

Contribution of IL-7 to the elimination of HIV-1 reservoirs/News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...